# Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

> **NCT00651508** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** KOS-1584

## Key facts

- **NCT ID:** NCT00651508
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2016-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00651508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00651508, "Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00651508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*